Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Nutritional factors may develop secondary to Mounjaro's effects on appetite and digestion
The company has recognized the growing demand for GLP-1 medications as an opportunity to expand its service offerings
In April 2025, AstraZeneca Plc could receive European Medicines Agency (EMA) approval for ECC5004, its oral GLP-1RA, for the treatment of obesity, intensifying competition in the oral treatment segment
LXR inhibition prevented fibrosis resolution in KDM5B/KDM5C deficient mice
The stronger the demand outlook, the more investors will ask whether supply, fill-finish, and oral capacity can keep up without pressuring margins
US$ 26.51
US$ 23.37
US$ 29.89
US$ 21.60
US$ 24.39
US$ 27.14
